Shandong Boan Biotechnology Company., Limited. Class H (HK:6955) has released an update.
Shandong Boan Biotechnology Co., Ltd. has issued a positive profit alert, expecting to report a profit of over RMB 60 million for the first half of 2024, a significant turnaround from the RMB 119 million loss in the same period the previous year. This anticipated profit is credited to increased sales of their products, especially the first domestically produced denosumab injection, cost reductions from manufacturing process improvements, and efficient management. The company advises shareholders and potential investors to await the official interim results announcement due in August 2024.
For further insights into HK:6955 stock, check out TipRanks’ Stock Analysis page.
